2024
Pacritinib Response Is Associated With Overall Survival in Myelofibrosis: PERSIST‐2 Landmark Analysis of Survival
Ajufo H, Bewersdorf J, Harrison C, Palandri F, Mascarenhas J, Palmer J, Gerds A, Kiladjian J, Buckley S, Derkach A, Roman‐Torres K, Rampal R. Pacritinib Response Is Associated With Overall Survival in Myelofibrosis: PERSIST‐2 Landmark Analysis of Survival. European Journal Of Haematology 2024 PMID: 39400386, DOI: 10.1111/ejh.14321.Peer-Reviewed Original ResearchSpleen volume reductionOverall survivalOS benefitNon-respondersAssociated with improved OSPatients treated with ruxolitinibAssociated with overall survivalAssociated with significant OS benefitImproved overall survivalSignificant OS benefitPERSIST-2Analysis of survivalUnique survival advantagesInhibitor of Janus kinaseJanus kinaseOS curvesRetrospective analysisSurvival advantageMyelofibrosisPacritinibPatientsRuxolitinibPlateletThrombocytopeniaVolume reduction
2023
Impact of Symptom Benefit and Transfusion Response on Survival in Myelofibrosis Patients Treated with Pacritinib: PERSIST-2 Landmark Survival Analysis
Ajufo H, Bewersdorf J, Harrison C, Palandri F, Mascarenhas J, Palmer J, Gerds A, Kiladjian J, Buckley S, Derkach A, Roman-Torres K, Rampal R. Impact of Symptom Benefit and Transfusion Response on Survival in Myelofibrosis Patients Treated with Pacritinib: PERSIST-2 Landmark Survival Analysis. Blood 2023, 142: 3207. DOI: 10.1182/blood-2023-177643.Peer-Reviewed Original ResearchLandmark survival analysisOverall survivalMyelofibrosis patientsNon-respondersTransfusion independenceRed blood cellsSymptom scoresOS benefitPERSIST-2Associated with OS benefitAssociated with improved OSRed blood cell transfusionAssociated with improved survivalSymptom benefitSurvival analysisEfficacy assessment periodSpleen volume reductionMedian platelet countLog-rank testMeasures of clinical benefitBAT armTotal symptom scoreUnique survival advantagesSymptom burden reductionAnemia improvementPOSTER: MPN-111 SVR (Spleen Volume Reduction) Predicts OS (Overall Survival) in MF (Myelofibrosis) Patients on PAC (Pacritinib) but Not BAT (Best Available Therapy): PERSIST-2 Landmark OS Analysis
Ajufo H, Bewersdorf J, Harrison C, Palandri F, Mascarenhas J, Palmer J, Gerds A, Kiladjian J, Buckley S, Derkach A, Roman-Torres K, Rampal R. POSTER: MPN-111 SVR (Spleen Volume Reduction) Predicts OS (Overall Survival) in MF (Myelofibrosis) Patients on PAC (Pacritinib) but Not BAT (Best Available Therapy): PERSIST-2 Landmark OS Analysis. Clinical Lymphoma Myeloma & Leukemia 2023, 23: s189. DOI: 10.1016/s2152-2650(23)00629-8.Peer-Reviewed Original ResearchMPN-111 SVR (Spleen Volume Reduction) Predicts OS (Overall Survival) in MF (Myelofibrosis) Patients on PAC (Pacritinib) but Not BAT (Best Available Therapy): PERSIST-2 Landmark OS Analysis
Ajufo H, Bewersdorf J, Harrison C, Palandri F, Mascarenhas J, Palmer J, Gerds A, Kiladjian J, Buckley S, Derkach A, Roman-Torres K, Rampal R. MPN-111 SVR (Spleen Volume Reduction) Predicts OS (Overall Survival) in MF (Myelofibrosis) Patients on PAC (Pacritinib) but Not BAT (Best Available Therapy): PERSIST-2 Landmark OS Analysis. Clinical Lymphoma Myeloma & Leukemia 2023, 23: s382-s383. DOI: 10.1016/s2152-2650(23)01218-1.Peer-Reviewed Original ResearchP1030: SPLEEN VOLUME REDUCTION PREDICTS SURVIVAL IN MYELOFIBROSIS PATIENTS ON PACRITINIB BUT NOT BEST AVAILABLE THERAPY: PERSIST‐2 LANDMARK OVERALL SURVIVAL ANALYSIS
Bewersdorf J, Ajufo H, Harrison C, Palandri F, Mascarenhas J, Palmer J, Gerds A, Kiladjian J, Derkach A, Roman‐Torres K, Buckley S, Rampal R. P1030: SPLEEN VOLUME REDUCTION PREDICTS SURVIVAL IN MYELOFIBROSIS PATIENTS ON PACRITINIB BUT NOT BEST AVAILABLE THERAPY: PERSIST‐2 LANDMARK OVERALL SURVIVAL ANALYSIS. HemaSphere 2023, 7: e44640da. PMCID: PMC10431555, DOI: 10.1097/01.hs9.0000971016.44640.da.Peer-Reviewed Original ResearchPERSIST-2Spleen volume reduction (SVR) predicts overall survival (OS) in myelofibrosis (MF) patients on pacritinib (PAC) but not best available therapy (BAT): PERSIST-2 landmark OS analysis.
Ajufo H, Bewersdorf J, Harrison C, Palandri F, Mascarenhas J, Palmer J, Gerds A, Kiladjian J, Derkach A, Rampal R, Buckley S, Roman-Torres K. Spleen volume reduction (SVR) predicts overall survival (OS) in myelofibrosis (MF) patients on pacritinib (PAC) but not best available therapy (BAT): PERSIST-2 landmark OS analysis. Journal Of Clinical Oncology 2023, 41: 7018-7018. DOI: 10.1200/jco.2023.41.16_suppl.7018.Peer-Reviewed Original ResearchSpleen volume reductionOverall survivalMF patientsNon-respondersOS benefitOS analysisSpleen volumePERSIST-2Median relative dose intensityAssociated with improved OSAssociated with improved survivalReduced spleen volumeAssociated with significant OS benefitRelative dose intensitySignificant OS benefitTreated with ruxolitinibLog-rank testUnique survival advantagesDose intensityProgressive cytopeniasMarrow fibrosisOS curvesSevere thrombocytopeniaPlatelet countSpleen reduction